Delving into the Latest Updates on Imatinib mesylate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

imatinib, imatinib mesilate, IMT

+ [33]

Target

Bcr-Abl x PDGFRα x c-Kit

Action

inhibitors

Mechanism

Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors), PDGFRα inhibitors(Platelet-derived growth factor receptor alpha inhibitors), c-Kit inhibitors(Stem cell growth factor receptor inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [5]

Active Indication

Accelerated phase Philadelphia chromosome positive chronic myeloid leukemiaPhiladelphia chromosome positive chronic myeloid leukemia in blast crisisPhiladelphia chromosome-positive chronic myeloid leukemia in chronic phase+ [27]

Inactive Indication

Abdominal NeoplasmsAcral Lentiginous Malignant MelanomaAcute Eosinophilic Leukemia+ [182]

Originator Organization

Novartis Pharma AG

Active Organization

Novartis Europharm Ltd.

The Children's Oncology Group Foundation, Inc.

Shorla Pharma Ltd.

+ [11]

Inactive Organization

Actavis Group PTC ehfJonsson Comprehensive Cancer Center

Novartis AG

+ [42]

License Organization

Hangzhou Chance Pharmaceuticals Co., Ltd.

Vectura Group Ltd.

Novartis AG

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (10 May 2001),

Philadelphia chromosome positive chronic myelogenous leukemia

RegulationAccelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC30H35N7O4S

InChIKeyYLMAHDNUQAMNNX-UHFFFAOYSA-N

CAS Registry220127-57-1

Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally. This study aims to evaluate the efficacy and safety of tofacitinib combined with imatinib in patients with moderate-to-severe PPP.

Start Date01 Aug 2026

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

NCT07585266

/ RecruitingPhase 3

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cause the cells to grow uncontrollably. Although current treatments may be effective, tumours may stop responding over time, highlighting the need for newer options. This study is evaluating velzatinib (GSK6042981) in participants with newly diagnosed GIST that has spread or cannot be surgically removed. Velzatinib will be compared with imatinib, the standard treatment, to assess whether it can delay disease worsening and is safe and well tolerated.

Start Date27 Jul 2026

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Imatinib mesylate

Login to view more data

100 Translational Medicine associated with Imatinib mesylate

Login to view more data

100 Patents (Medical) associated with Imatinib mesylate

Login to view more data

17,470

Literatures (Medical) associated with Imatinib mesylate

01 Mar 2027·TALANTA

Terbium-modified poly(diphenylamine orange) sensor enabling sustainable monitoring of imatinib: Voltammetric and DFT insights

Article

Author: Darwish, Ibrahim A ; Hosny, Noha M ; Frontera, Antonio

Therapeutic drug monitoring (TDM) of imatinib (IMB), a first-line tyrosine kinase inhibitor, is clinically essential due to its narrow therapeutic window and significant inter-individual pharmacokinetic variability. Existing analytical methods for IMB quantification suffer from limitations including high operational costs, complex sample preparation, toxicity concerns (mercury-based electrodes), and time-consuming procedures. This study describes the first-ever fabrication and application of a novel electrochemical sensor based on a terbium-modified polymerized diphenylamine orange composite on a pencil graphite electrode (Tb@poly-DPO/PGE) for sensitive, selective, and sustainable determination of IMB. The Tb@poly-DPO/PGE sensor was fabricated via sequential electropolymerization of DPO onto PGE followed by electrodeposition of Tb ions. The sensor was characterized using scanning electron microscopy, cyclic voltammetry, and electrochemical impedance spectroscopy. The Tb@poly-DPO/PGE sensor exhibited superior electrochemical performance with significantly enhanced electroactive surface area (0.175 cm²) and reduced charge-transfer resistance (112.0 Ω). Density functional theory (DFT) calculations were employed to investigate molecular-level interactions. A square-wave voltammetric (SWV) method was developed and validated according to ICH and EMA guidelines for IMB quantification in bulk solutions and spiked human plasma samples. The SWV method demonstrated linear response in two concentration ranges (0.025-0.5 μM and 1.0-4.5 μM) with a detection limit of 5.46 nM. The method showed acceptable trueness (recovery: 99.91-100.46%), precision (RSD ≤ 1.14%), selectivity, and stability over 20 days. Successful application to spiked human plasma samples demonstrated minimal matrix effects. The proposed method demonstrated superior analytical throughput (15 samples/hour in batch mode) and sustainability, achieving an Environmental, Performance, and Practicality Index score of 78.2. The fabricated sensor provides a robust, environmentally sustainable, and practically feasible platform for routine TDM of IMB, offering a promising alternative to existing analytical methodologies pending further validation on authentic patient samples.

31 Dec 2026·Gut Microbes

Fusobacterium nucleatum plays a pathogenic role in a murine model of irritable bowel syndrome by modulating intestinal purine metabolism and promoting mast cell activation

Article

Author: Zhou, Yesheng ; Hou, Songyuan ; Zhu, Jiaqi ; Ye, Haozhen ; Zhu, Shengtao ; Ning, Tingting ; Wang, Chenxu ; Liu, Si ; Zhang, Nan ; Lu, Shaochong ; Yang, Xinyi

Gut microbiota dysbiosis has been implicated in the pathogenesis of irritable bowel syndrome (IBS), a globally prevalent functional gastrointestinal disorder; however, mechanistic insights remain limited. We determined that the bacterium Fusobacterium nucleatum (F. nucleatum) played a pathogenic role in a murine model of IBS. Monocolonization of antibiotic-treated or germ-free mice with F. nucleatum induced IBS-like symptoms, including visceral hypersensitivity, increased fecal water content, and accelerated gastrointestinal transit, accompanied by mast cell activation. These effects were effectively prevented by treatment with the antibiotic metronidazole, as well as by the mast cell depleting agent imatinib or the mast cell stabilizer sodium cromoglicate. Mechanistically, F. nucleatum upregulated the expression of purine nucleoside phosphorylase (PNP) in intestinal epithelial cells (IECs), a key enzyme in the purine degradation pathway. The elevated PNP activity promoted purine degradation and uric acid production in IECs, which in turn directly activated mast cells. This F. nucleatum-driven mast cell activation mediated IBS-like symptoms in ABX treated mice but was abrogated by blocking uric acid synthesis. In summary, our findings highlight the crucial role of purine metabolism reprogramming and low-grade mucosal immune responses in F. nucleatum-mediated IBS-like symptoms in mice, providing promising therapeutic perspectives for targeting F. nucleatum-positive IBS patients.

31 Dec 2026·Future Science OA

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications

Article

Author: Andrews, Michael B. ; Thompson, Cameron M. ; Adler, Douglas G.

BACKGROUND:

Treatments for metastatic, unresectable, or treatment-resistant gastrointestinal stromal tumors (GIST) include avapritinib, imatinib, regorafenib, ripretinib, and sunitinib. The FDA Adverse Event Reporting System (FAERS) database collects medication-related adverse events (AEs).

DESIGN AND METHODS:

Reports in the FAERS database from each medication's FDA approval to June 30, 2025 were analyzed. Reports containing other medications or indications outside of GIST treatment were excluded.

RESULTS:

Avapritinib was associated with fatigue (n = 826, 10.2%), nausea/vomiting (n = 574, 7.1%), eye/facial swelling (n = 631, 7.8%), diarrhea n = 361, 4.5%), peripheral edema (n = 231, 2.5%). Imatinib was associated with nausea/vomiting (n = 677, 4.4%), fatigue (n = 549, 3.6%), anemia (n = 404, 2.6%), abdominal pain (n = 400, 2.6%), and rash (n = 340, 2.2%), hemorrhage (317 AEs, 2.1%). Regorafenib was associated with fatigue (n = 104, 8.6%), palmar-plantar erythrodyesthesia syndrome (n = 66, 5.4%), diarrhea (n = 60, 4.9%). Ripretinib was associated with fatigue (n = 534, 8.4%), alopecia (n = 355, 5.6%), nausea/vomiting (n = 273, 4.3%). Sunitinib was associated with fatigue (n = 420, 6.1%%), nausea/vomiting (n = 284, 4.2%), diarrhea (n = 262, 3.8 %), hemorrhage (n = 149, 2.2%).

CONCLUSIONS:

The FAERS database revealed multiorgan AEs associated with five GIST treatment medications. Novel findings include eye/facial and peripheral edema with avapritinib, palmar-plantar erythrodyesthesia syndrome, headache/migraine, and gait abnormalities across all five medications, pancytopenia with imatinib, and hemorrhage with imatinib and sunitinib.

505

News (Medical) associated with Imatinib mesylate

20 Oct 2026

·www.inhibikase.com

Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors

WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced the appointment of Scott M. Wasserman, MD, to the Company’s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman’s appointment, the Company also announced the resignation of Dennis Berman from the Company’s Board. “We thank Dennis for his many contributions to the Company during his years of service,” said Amit Munshi, Chair of the Inhibikase Board of Directors. Dr. Wasserman is currently the Chief Medical Officer of Kailera Therapeutics, a clinical-stage company developing GLP-1-based therapeutics for obesity and related conditions. Dr. Wasserman is a cardiologist with more than two decades of experience in clinical development and company leadership. At Amgen Inc., he served as Vice President, Global Development and Therapeutic Area Head for Bone, Cardiovascular, Metabolic and Neuroscience. He was Amgen’s first cardiologist and built the company’s cardiovascular and metabolic strategy, team and portfolio. He led the global development and approvals of Repatha (evolocumab), was instrumental in the development and U.S. FDA approval of Evenity (romosozumab) and oversaw the U.S. approval of Aimovig (erenumab). “Scott has taken multiple programs from early development through global approval, and he has built clinical organizations at both large and emerging companies,” said Amit Munshi. “We look forward to benefiting from his expertise as we continue to advance our global Phase 3 IMPROVE-PAH study of IKT-001. We are pleased to welcome Scott to our Board. “PAH is a progressive, life-threatening disease, and the pedigree of imatinib together with the recent preclinical and Phase 1 data for IKT-001 point to a very promising role for this asset in this difficult to treat condition,” said Dr. Wasserman. “This is an important time for Inhibikase, and I look forward to applying my experience in global clinical development and regulatory interactions as the Company advances IMPROVE-PAH.” Scott brings deep expertise in clinical development to Inhibikase’s Board of Directors, spanning global development strategy, clinical trial design and execution, and global regulatory interactions. Most recently, Scott served as Venture Partner at Frazier Life Sciences, focusing on company creation. Prior to Frazier, Scott was the CEO and co-founder of Latigo Biotherapeutics, a venture-backed biotechnology company developing first and best-in-class, non-opioid pain medicines. Prior to his role with Latigo, Scott was Vice President, Global Development Therapeutic Area Head for Bone, Cardiovascular, Metabolic, and Neuroscience at Amgen. In addition to his role in the development of Repatha, Evenity, and Aimovig, Scott oversaw therapeutic development for a range of other conditions, including heart failure, anemia, obesity, and Alzheimer’s disease. Prior to joining industry, Scott was on faculty at Stanford University in the Division of Cardiovascular Medicine conducting NIH-sponsored research on endothelial gene expression and served as a non-interventional cardiologist at the Veterans Administration Hospital in Palo Alto, CA. Scott received his BS, Magna Cum Laude from Haverford College and his MD, Magna Cum Laude from Harvard Medical School. He completed his postgraduate training in Internal Medicine and Cardiovascular Medicine at Stanford University and post-doctoral cardiovascular research at COR Therapeutics, Millennium Pharmaceuticals, and Stanford. About Inhibikase (www.inhibikase.com) Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients. Social Media Disclaimer Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential of IKT-001, the advancement of the IMPROVE-PAH study, and the anticipated contribution of Dr. Wasserman to the Company's board of directors. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contacts: Investor Relations: Michael Moyer LifeSci Advisors mmoyer@lifesciadvisors.com Released October 20, 2026

Drug ApprovalExecutive ChangePhase 1Phase 3

05 Oct 2026

·www.biospace.com

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 128,000 shares of the Company’s common stock to two newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of September 30, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $2.055 per share, which is equal to the closing price of the Company’s common stock on the Effective Date. The options have a ten year term, with 25% vesting on the first anniversary of the Effective Date and the remaining 75% vesting in 36 equal monthly installments thereafter. The options are subject to the terms and conditions of the Inducement Plan approved by the Company’s Board of Directors in March 2026 and the terms and conditions of award agreements covering the grants. About Inhibikase Therapeutics Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety pro the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH ( I KT-001 for M easuring P ulmonary Vascular R esistance and O utcome V ariables in a Phase 3 E valuation of PAH ), is actively enrolling patients. Contacts: Investor Relations: Michael Moyer LifeSci Advisors mmoyer@lifesciadvisors.com

21 Sep 2026

·www.prnewswire.com

Grünenthal acquires cancer treatment Stivarga®

Latest step in Grünenthal's strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth. Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma (liver cancer). It is approved and available in more than 90 markets worldwide. Grünenthal has invested around €2.6 billion in successful M&A transactions since 2017, significantly strengthening its profitability and further funding its innovative research pipeline. AACHEN, Germany, Sept. 21, 2026 /PRNewswire/ -- Grünenthal, a global leader in pain management and research, today announced an agreement with Bayer AG to acquire Stivarga®, an oral treatment for specific advanced cancers, for up to €375 million. The acquisition is subject to customary closing conditions, including approval by the relevant regulatory authorities. The acquisition is expected to close by the end of 2026 or early 2027. Stivarga® (regorafenib) is an oral multkinase inhibitor indicated for metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumours (GIST) in patients who have already been treated with, or who cannot be given, other available treatments. It is approved and available in more than 90 markets worldwide. "This acquisition is a strong strategic fit for Grünenthal and reflects our disciplined M&A strategy of acquiring established medicines that address clear and ongoing medical needs and create long-term value," said Gabriel Baertschi, CEO, Grünenthal. "Stivarga® has a well-established role in patient care and the transaction is immediately accretive to our business. By leveraging the strength of our commercial and operational expertise, we see clear opportunities to maximise the value of the medicine and support Grünenthal's long-term growth." Loss of exclusivity for Stivarga® is anticipated in 2029 in the European Union and in 2030 in the United States (US). Grünenthal estimates that Stivarga® may contribute a positive impact on its consolidated EBITDA of up to approximately €100 million for the year ending 31 December 2027, based on an analysis of the information made available to Grünenthal from Bayer and assuming closing by the end of 2026 or the beginning of 2027, as well as a full-year consolidation. The acquisition is the latest development in Grünenthal's M&A strategy and follows the successful integration of several important medicines across a range of health conditions, including the global rights to Nebido™, the rights to Cialis® in Mexico, Brazil and Colombia, the European rights to Crestor™ and Nexium™, and the global rights to Vimovo™ (ex-US and Japan), Zomig™ (ex-Japan) and Qutenza™. In addition to asset acquisitions, earlier this year, Grünenthal acquired full ownership of Grünenthal Meds, a previously joint venture with Kyowa Kirin International to market its established medicines portfolio, and, in 2024, acquired the US company Valinor Pharma and the product Movantik®. The company has invested around €2.6 billion in successful M&A transactions since 2017. About Stivarga ® Stivarga® is a once-daily, oral prescription medicine for certain advanced cancers. It has treated more than one million patients across more than 90 countries over 10 years. In the EU, Stivarga® is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy, as well as for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib, and for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. In the US, Stivarga® is indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy, as well as locally advanced, unresectable or metastatic GIST who have been previously treated with imatinib mesylate and sunitinib malate, and for HCC who have been previously treated with sorafenib. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion. More information: Follow us on LinkedIn & Instagram Advisors Freshfields served as legal counsel to Grünenthal. For further information, please contact: Matt Crabb, Head of Global Communications (Interim), Grünenthal [email protected] SOURCE Grünenthal Group 21% more press release views with Request a Demo

AcquisitionDrug Approval

100 Deals associated with Imatinib mesylate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01441	Imatinib mesylate	L01EA01	DB00619

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia	United States	Shorla Pharma Ltd.	22 Nov 2024
Philadelphia chromosome positive chronic myeloid leukemia in blast crisis	United States	Shorla Pharma Ltd.	22 Nov 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	United States	Shorla Pharma Ltd.	22 Nov 2024
Chronic phase chronic myeloid leukemia	European Union	Teva Pharmaceuticals Europe BV	07 Jan 2013
Chronic phase chronic myeloid leukemia	Iceland	Teva Pharmaceuticals Europe BV	07 Jan 2013
Chronic phase chronic myeloid leukemia	Liechtenstein	Teva Pharmaceuticals Europe BV	07 Jan 2013
Chronic phase chronic myeloid leukemia	Norway	Teva Pharmaceuticals Europe BV	07 Jan 2013
Metastatic Gastrointestinal Stromal Tumor	European Union	Teva Pharmaceuticals Europe BV	07 Jan 2013
Metastatic Gastrointestinal Stromal Tumor	Iceland	Teva Pharmaceuticals Europe BV	07 Jan 2013
Metastatic Gastrointestinal Stromal Tumor	Liechtenstein	Teva Pharmaceuticals Europe BV	07 Jan 2013
Metastatic Gastrointestinal Stromal Tumor	Norway	Teva Pharmaceuticals Europe BV	07 Jan 2013
Myeloproliferative Disorders	European Union	Teva Pharmaceuticals Europe BV	07 Jan 2013
Myeloproliferative Disorders	Iceland	Teva Pharmaceuticals Europe BV	07 Jan 2013
Myeloproliferative Disorders	Liechtenstein	Teva Pharmaceuticals Europe BV	07 Jan 2013
Myeloproliferative Disorders	Norway	Teva Pharmaceuticals Europe BV	07 Jan 2013
Ph-Like Acute Lymphoblastic Leukemia	European Union	Teva Pharmaceuticals Europe BV	07 Jan 2013
Ph-Like Acute Lymphoblastic Leukemia	Iceland	Teva Pharmaceuticals Europe BV	07 Jan 2013
Ph-Like Acute Lymphoblastic Leukemia	Liechtenstein	Teva Pharmaceuticals Europe BV	07 Jan 2013
Ph-Like Acute Lymphoblastic Leukemia	Norway	Teva Pharmaceuticals Europe BV	07 Jan 2013
Philadelphia Chromosome Positive Leukemia	European Union	Teva Pharmaceuticals Europe BV	07 Jan 2013

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Idiopathic pulmonary arterial hypertension	Phase 3	United States	Jade Biosciences, Inc.	04 Apr 2022
Idiopathic pulmonary arterial hypertension	Phase 3	Argentina	Jade Biosciences, Inc.	04 Apr 2022
Idiopathic pulmonary arterial hypertension	Phase 3	Australia	Jade Biosciences, Inc.	04 Apr 2022
Idiopathic pulmonary arterial hypertension	Phase 3	Austria	Jade Biosciences, Inc.	04 Apr 2022
Idiopathic pulmonary arterial hypertension	Phase 3	Belgium	Jade Biosciences, Inc.	04 Apr 2022
Idiopathic pulmonary arterial hypertension	Phase 3	Bulgaria	Jade Biosciences, Inc.	04 Apr 2022
Idiopathic pulmonary arterial hypertension	Phase 3	Canada	Jade Biosciences, Inc.	04 Apr 2022
Idiopathic pulmonary arterial hypertension	Phase 3	Chile	Jade Biosciences, Inc.	04 Apr 2022
Idiopathic pulmonary arterial hypertension	Phase 3	Czechia	Jade Biosciences, Inc.	04 Apr 2022
Idiopathic pulmonary arterial hypertension	Phase 3	Denmark	Jade Biosciences, Inc.	04 Apr 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2026	Not Applicable	Gastrointestinal Stromal Tumors	39	Imatinib 400 mg/day	xeoikiwxde(nucpvvaqca) = tedxsujblv nbusewextd (upqupjflqs ) View more	Positive	23 Oct 2026
ESMO2026	Not Applicable	Gastrointestinal Stromal Tumors Neoadjuvant	45	Preoperative imatinib	igfkzpslur(kfwedxzyox) = sdlozmeogc rsvhppfdlr (fkmuphjxfi ) View more	Positive	23 Oct 2026
CSCO2026	Not Applicable	Ph+	50	伊马替尼联合CCCG-ALL-2015方案	fbipsjzfgn(oragcmmxll) = bsqocgbgvt lrsccktlha (etobagwetq, 24.2 - 53.8) View more	Positive	11 Sep 2026
CSCO2026	Not Applicable	Ph+	50	达沙替尼联合CCCG-ALL-2015方案	cyhhpwpgzf(hhaktrxqle) = bsypewmkca zfzihvslzd (dqakmohsbe, 35 - 64.3) View more	Positive	11 Sep 2026
ASCO_Breakthrough2026	Not Applicable	Chronic Myelogenous Leukemia	248	imatinib	hplsdtghzs(aonczxnwat) = fdakztxutb ztnobgeuiq (bdsnhqtrme ) View more	Positive	25 Jun 2026
ASCO_Breakthrough2026	Not Applicable	Chronic Myelogenous Leukemia	248	second-generation tyrosine kinase inhibitors	hplsdtghzs(aonczxnwat) = dkfnixmunt ztnobgeuiq (bdsnhqtrme ) View more	Positive	25 Jun 2026
ASCO2026	Not Applicable	Chronic phase chronic myeloid leukemia	440	Imatinib (Chronic myeloid leukemia + Excluded TFR patients)	clbcnclzqt(dofjksemui) = vwgtvjsdio dxqrovnrdx (fldhofqiuc ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Gastrointestinal Stromal Tumors Neoadjuvant KIT exon 11 mutations	131	Brand-name imatinib	nkqifbjduo(sxpkhulnil) = lrwuhcpvdf adbsojjemr (rfulhouczj ) View more	Positive	29 May 2026
ASCO2026	Not Applicable		131	Generic imatinib	lyrtjscvnf(stihsbxopw) = oitwuiwenm vfdyjvyazp (kyuuraieyp )	Positive	29 May 2026
ASCO2026	Not Applicable	Gastrointestinal Stromal Tumors First line	124	Imatinib 400mg/day	kekwueopva(oveucrlqcp) = 35.6% eudklorgvp (qozknqocqk ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Chronic Myelogenous Leukemia First line	1,944	Second-generation TKIs (nilotinib, dasatinib, bosutinib)	jfjqumecpe(flglniikps): RR = 1.28 (95.0% CI, 0.85 - 1.92), P-Value = 0.24 View more	Negative	29 May 2026
ASCO2026	Not Applicable	Chronic Myelogenous Leukemia First line	1,944	Imatinib		Negative	29 May 2026
EHA2026	Not Applicable	Chronic Myelogenous Leukemia	45	Imatinib	qevlbwbrws(iflazvlhuw) = gippefiaqq fufjiouvyd (izxkdrkbkr )	Negative	12 May 2026
EHA2026	Not Applicable	Chronic Myelogenous Leukemia Philadelphia chromosome-positive	1	Imatinib 400 mg daily	vwbceeaqpy(xuccknactq) = zcpmtrkhds shjmpuyenz (enawxpqvgi )	Positive	12 May 2026